螺[1-氯-4-l-孟氧基-5-氧杂-6-氧代双环[3·1·0]己烷-2,3'-(4'-吗啉基-5'-l-孟氧基丁内酯)]合丙酮的合成及晶体结构

利用新手性源,5-(l-孟氧基)-3-氯-2(5H)-呋喃酮4与亲核试剂吗啉通过串联不对称双Michael加成/分子内亲核取代反应合成了一般方法难以得到的含有多个手性中心的螺-环丙烷双内酯化合物C32H50O7NCl.其单晶为C32H50O7NCl(OC3H6)0.5,正交晶系, 空间群为P212121, 晶胞参数a = 17.149(3), b = 20.384(4), c = 10.831(2) , V = 3786.1(12) 3, Z = 4, Dc = 1.097 g/cm3, F(000) = 1352, μ= 0.144 mm-1; 射线类型为MoK?( = 0.71073 ?, 偏离因子R = 0.0755, wR = 0.1956, 独立衍射点3710个, 其中可观测点数2318个.分子中共有六个环, 12个手性中心, 3个六元环呈椅式构象, 两个五员内酯环呈信封式构象, 并分别与环丙烷形成[2.4]螺环和 [3.1.0] 稠环, 4个新生成的手性中心的绝对构型为C(3)(S), C(4)(S), C(5)(R), C(8)(R).     

螺〔1-溴-4-l-孟氧基-5-氧杂-6-氧代双环〔3.1.0〕己烷2,3’-(4’-甲氧基5’孟氧基丁内酯)〕的晶体结构

本文报道了利用新手性源合成的标题化合物C2 9H45 BrO7(Mr=5 85 .5 6 )的晶体结构 ,该晶体属正交晶系 ,空间群为P2 1 2 1 2 1 ,晶胞参数a =9.748(4) ,b =12 .5 37(5 ) ,c =2 5 .85 1(9) ,V =315 9(2 ) 3,Z =4,Dx=1.2 31g/cm3,μ =1.341mm- 1 ,F(0 0 0 ) =12 40 ,偏离因子R =0 .0 475 ,Rw=0 .0 6 0 9;分子中共有 5个环 ,12个手性中心 ,2个六元环呈椅式构象 ,2个五元内酯环呈信封式构象 ,并分别与环丙烷形成〔2 .4〕螺环和〔3 .1.0〕稠环 ,4个新生成的手性中心的绝对构型为C(13) (S) ,C(14 ) (S) ,C(15 ) (R) ,C(16 (R) ,无任何对称因素     

螺{1-溴-4-L-孟氧基-5-氧杂-6-氧代双环[3.1.0]己烷-2,3′-(4′-呋喃甲醇基-5′-孟氧基丁内酯)}的合成及其晶体结构

α-呋喃甲醇与手性试剂5-(L-孟氧基)-3-溴-2(5H)-呋喃酮于室温进行串联的不对称双M ichael加成/分子内亲核取代反应,合成了含有4个新手性中心的螺环/环丙烷标题化合物(1,C33H47B rO8,M r=651.62)。其结构经1H NMR,13C NMR,IR,MS,元素分析和四园单晶X-射线衍射仪表征。1属正交晶系,P2(1)2(1)2(1)空间群,a=10.166(2),b=14.980(3),c=23.202(5),α=90°,β=90°,γ=90°,V=3533.4(12)3,Z=4,Dc=1.225 Mg.m-3,μ=0.074 mm-1,F(000)=1376,偏离因子R=0.0701,wR=0.1149。1的分子中共有6个环,12个手性中心,2个六元环呈椅式构象,3个五元环呈信封式构象,4个新生成的手性中心的构型分别是(S)-C1,(S)-C3,(R)-C3,′(R)-C4′。     

螺{1-溴-4-L-孟氧基-5-氧杂-6-氧代双环[3.1.0]己烷-2,3''''-(4''''-呋喃甲醇基-5''''-孟氧基丁内酯)}的合成及其晶体结构

α-呋喃甲醇与手性试剂5-(L-孟氧基)-3-溴-2(5H)-呋喃酮于室温进行串联的不对称双Michael加成/分子内亲核取代反应,合成了含有4个新手性中心的螺环/环丙烷标题化合物(1, C33H47BrO8, Mr=651.62). 其结构经1H NMR, 13C NMR, IR, MS,元素分析和四园单晶X-射线衍射仪表征.1属正交晶系, P2(1)2(1)2(1)空间群, a=10.166(2) (°A), b=14.980(3) (°A), c=23.202(5) (°A), α=90°, β=90°, γ=90°, V=3533.4(12) (°A)3, Z=4, Dc=1.225 Mg·m-3, μ=0.074 mm-1, F(000)=1376,偏离因子R=0.0701, wR=0.1149. 1的分子中共有6个环,12个手性中心,2个六元环呈椅式构象,3个五元环呈信封式构象,4个新生成的手性中心的构型分别是 (S)-C1, (S)-C3, (R)-C3', (R)-C4'.     

三有机锡(4R)-3-[[(2S)-5-氧-2-吡咯烷基]羰基]-4-噻唑烷甲酸酯的合成、结构和体外抗癌活性

利用三有机锡氢氧化物和手性配体(4R)-3-[[(2S)-5-氧-2-吡咯烷基]羰基]-4-噻唑烷甲酸(HL)反应合成了3个三有机锡(4R)-3-[[(2S)-5-氧-2-吡咯烷基]羰基]-4-噻唑烷甲酸酯R3SnL[1,R=c-C6H11(a),C6H5(b),C6H5C(CH3)2CH2(c)],通过元素分析、IR、1H NMR和X-射线单晶衍射表征了其结构。化合物1a属正交晶系,P212121空间群;化合物1b属单斜晶系,P21空间群。二者均为由羧基氧和内酰胺羰基氧桥联配位形成的右螺旋链状有机锡配位聚合物,锡原子具有五配位[SnC3O2]畸变三角双锥构型。化合物1a和1b对体外2种人癌细胞Colo205和Bcap37增殖均有强的抑制作用,其活性为1b1a。     

(2S,4R)-2-(溴甲基)-2-(2,4-二氯苯基)-1,3-二氧环戊环-4-甲基苯甲酸酯的合成及晶体结构

合成了标题化合物并测定了其晶体结构。该化合物的化学式为C18H15O4BrCl2, Mr = 446.12。晶体为正交晶系, P212121空间群, 晶胞参数为: a = 7.1540(7), b = 23.367(1), c = 11.161(2) , V = 1865.7(3) 3, Z = 4, Dc = 1.588 g/cm3, F(000) = 896, (MoK? = 2.515 cm-1, R = 0.037, wR = 0.074, Flack系数为0.14(1)。晶体结构显示, 化合物中有2个手性碳原子, 为(2S,4R)构型, 整个分子呈沿b轴排列的波浪形的链状结构。     

手性5-(R)-(1′R,2′S,5′R)-孟氧基丁内酯并[3,4-b]-2(S)-6(R)-1-N-环己基氮杂环丙烷的合成及晶体结构

环己胺与手性元5-(R)-(1′R,2′S,5′R)-孟氧基-3-溴-2(5H)-呋喃酮的不对称M ichael加成/分子内亲核取代反应,得到含有两个新手性中心的氮杂环丙烷/稠合丁内酯标题化合物。对其进行了谱学表征和X-射线单晶衍射测定。标题化合物分子式为C20H33NO3,M r=335.47,三斜晶系,P1空间群,晶胞参数:a=5.438(11)。A,b=8.117(2)。A,c=11.572(2)。A,α=96.84(3)°,β=94.48(3)°,γ=101.86(3),°V=493.5(2)。A3,Z=1,D c=1.129g/cm3,R=0.0867,wR=0.2344。     

3-(3,4-亚甲二氧基)苯基-6-孟氧基-6,6a-二氢-呋喃并[3,4-d]异噁唑啉-4(3aH)-酮的合成和晶体结构

标题化合物是由5-(R)-(l-孟氧基)-2(5H)-呋喃酮与3,4-亚甲二氧基苯甲醛肟在次氯酸钙作为氧化剂的条件下,进行的区域选择性原位1,3-偶极环加成反应得到。结构通过单晶X-射线衍射法确定, C22H27NO6其晶体属正交晶系, 空间群为P212121, Mr = 401.45, a = 6.2600(3), b = 10.7300(11), c = 31.2160(25) , V = 2096.8(3) 3, Z = 4, Dc = 1.272 g/cm3, μ = 0.09 mm-1, F(000) = 856。最终的可靠因子为R f = 0.073, wR = 0.186。在分子结构中,平面1(异噁唑啉环)与平面2(呋喃酮环)之间的二面角为67.4°, 孟氧基中的环己烷环为椅式构象,呋喃酮并异噁唑啉环上的3个手性中心的构型为SC3a, RC6, RC6a。     

(1R,4S,5S)-6-环己基-4-[(1R,2S,5R)-5-甲基-2-异丙基环己氧基]-3-氧杂-6-氮杂双环[3.1.0]-2-己酮的合成及结构表征

环已胺与差向异构体5-[(1R,2S,5R)-5-甲基-2-异丙基环己氧基]-3-溴-2(5H)-呋喃酮发生不对称Mi-chael加成-分子内亲核取代反应,并经柱层析分离,得到一对手性氮杂环丙烷-丁内酯衍生物,其中的标题化合物为首次得到的新手性化合物,产率17%,其结构经IR、1H NMR、13C NMR和HRMS进行了表征。     

钼簇合物反应性能的研究: {Mo3S4[S2P(OEt)2]4H2O}的加硫反应以及产物{Mo3(μ3-S)(μ-S2)3[S2P(OEt2]3I}的晶体结构

由贫硫化合物{Mo_3S_4[S_2P(OEt)_2]_4·H_2O}通过加硫获得了富硫化合物{Mo_3S_7[S_2P(OEt)_2]_3·I}(CH_8C_6H_5).化合物属三斜晶系,空间群PI,晶胞参数为a=10.350(1)A,b=13.931(4)A,c=16.369(3)A,α=103.69(2),β=86.62(1),γ=111.99(2)°,V=2183A~3;z=2,D_c=1.817g·cm~(-3).最终结构偏离因子R为0.042. 簇分子{Mo_3(μ_3-S)(μ-S_2)_3[S_2P(OEt)_2]3·I}属{Mo_3(μ3一Y)(μ-S_2)_3[S_2P(OEt)_2]_3·X}(Y=O,S;X=Cl,I)系列构型.{Mo_3}基本上是一个正三角形,Mo—Mo键长分别为2.721(1),2.724(1),2.725(1)A,Mo的配位多面体为七个硫原子组成的畸变五角双锥,有一个I原子联结着三个(S_2)~(2-)桥基的三个不与Mo共平面的S原子,I—S距离平均为3.169A,比相应的Van der Waals距离(～4.00A)明显地短,显示一定程度的成键作用,簇分子的这一构型是一种较为稳定的结构类型.     

Synthesis and Crystal Structure of N,N′-Bis-[3-chloro-5-S-(l-menthyloxy)-2(5H)-4-furanon-yl]-propane-1,3-diamine

The title compound,N,N′-bis-[3-chloro-5-S-(l-menthyloxy)-2(5H)-4-furanon-yl]-propane-1,3-diamine(C31H48Cl2N2O6,Mr = 615.61),has been synthesized and characterized by IR,1H NMR,MS,elemental analysis and single-crystal X-ray diffraction.The crystal crystallizes in the monoclinic system,space group C2 with a = 16.1091(4),b = 11.1880(3),c = 19.2854(5) ,β = 106.297(2)°,V = 3336.12(15) 3,Z = 4,Dc = 1.226 mg/m3,μ = 0.237 mm-1,F(000) = 1320,the final R = 0.0531 and wR = 0.0700 for 2760 observed reflections(I > 2σ(I)).X-ray analysis reveals that the title compound possesses four rings:two chiral five-membered furanone rings and two six-membered cyclohexane rings with chair conformation,containing eight chiral centers:C2(S),C3(R),C5(R),C10(S),C18(S),C21(R),C22(S) and C25(R).The structure is stabilized by N-H…O hydrogen bonding interaction.     

Synthesis and Crystal Structure of 5（R）-（1R,2S,5R）-Menthoxy-4（R）- N-cyclohexylaminobutyrolactone

1INTRODUCTION Substitutedγ-butyrolactones are a group of impor-tant compounds containing unique carbon skeleton of butyrolactone which is widely present in many natural products and have received considerable interest because of their biological and medicinal properties[1～4].Therefore,much attention has been paid to the new asymmetric methods for synthesi-zing these interesting compounds[5～11].The prece-ding results led us to explore the possibility of using cyclohexylamine to convert5(…     

Synthesis and Crystal Structure of Spiro[1-bromo(S)-4-(R)-hydroxy- 5-oxa-6-oxo-bicyclo[3.1.0]hexane-2,2''-(3''-diethyl-(-(S)-4''-Cl-benzyloxyphosphonyl-4''-(1R,2S,5R)-menthyloxybutyrolactone)]

The title compound, spiro[1-bromo(S)-4-(R)-hydroxy-5-oxa-6-oxo-bicyclo[3.1.0]-hxane-2,2'-(3'-diethyl-α-(S)-4'-Cl-benzyloxyphosphonyl-4'-(1R,2S,5R)-menthyloxybutyrolactone)] has been synthesized via the tandem asymmetric reaction and it crystallizes in a monoclinic system, space group P21 with a = 11.067(3), b = 12.484(2), c = 12.356(2)(A), β = 101.95°,C29H39BrC1O10P, Mr = 693.93, V= 1670.2(6) (A)3, Z= 2, Dc= 1.380 g/cm3, λ(MoKα) = 0.071073nm, μ = 1.410 mm-1, F(000) = 720, the final R = 0.0570 and wR = 0.0758 for 6190 observed reflections with I ＞ 2σ(I). The structure is characterized by the special combination of biologic phosphonyl group and one cyclopropane as well as two butyrolactones. The intermolecular hydrogen bond between O(3)-H(3A)…O(10) in the crystal lattice has been observed.     

Synthesis and Crystal Structure of 4-(Dichloroacetyl)-1-oxa-4-azaspiro[4.5]decane

<正>The title compound 4-(dichloroacetyl)-1-oxa-4-azaspiro[4. 5] decane (CAS number 71526-07-3, C10H15Cl2NO2, Mr= 252.13) was obtained by the reaction of dichloroacetic acid with 1-oxa-4-azaspiro[4. 5] decane. The crystal is of monoclinic, space group P21ln with the unit cell constants: a = 5.9619(4),b= 10.0066(8), c = 20.0986(4) A,β = 90.194(3)°, V= 1199(4) A3,Z = 4, Dc= 1.397 g/cm3, F(000) = 528, μ(MoKα) = 0.522 mm-1, R = 0.0611 and wR = 0.1656 for 1276 observed reflections (I > 2σ(I)). X-ray analysis reveals that the cyclohexyl adopts a chair conformation and the compound is a chiral one.     

Synthesis and Crystal Structure of (2S,2'S,4'R)-2-(1-Hydroxy-1-ethylpropyl)-1-[(1'-p-tosyl-4'-hydroxypyrrolidin-2'-yl)methyl]pyrrolidine

1 INTRODUCTION In recent years, chiral β-amino alcohols have attracted much attention due to their special bio- logical functions and catalytic activities. Chiral β- amino alcohol moieties are usually found not only in natural products (e.g., cinchona alkaloids, ephe- drine, toxal, etc.) with special biological activities[1, 2], but also critical structural segments of some syn- thesized biologically active compounds, such as adrenergic agonists or antagolist[3, 4] and inhibitors for HI…     

Crystal Structure of (6S,9S,13R,14S)-7,8-Didehydro-3,7-dimethoxy-17-methylmorphinan-4,6-diol

1 INTRODUCTION (9S,13R,14S)-7,8-Didehydro-3,7-dimethoxy-4-hydroxy-17-methylmorphinan-6-one I is an impor- tant natural product that was used to ease pain, decrease blood pressure and diminish inflammation. In order to study the stereochemistry of the reduction of I with potassium boronhydride, the crystal structure of the title compound II was determined by X-ray diffraction method. 2 EXPERIMENTAL 2. 1 Instrument The melting point was measured on a Yanagimoto MP-500 apparatus…     

Synthesis and Crystal Structure of 1-（4-Bromobenzoyl）-3- [5-（E）-styryl-1,3,4-thiadiazol-2-yl]urea

1 INTRODUCTION 1,3,4-Thiadiazole derivatives represent an interes- ting class of compounds possessing broad spectrum biological activities[1~4]. Aroyl ureas are known to exhibit diverse biological effects, such as insecticidal, fungicidal, herbicidal and plant growth regulating activities[5~8]. Therefore, it is worthwhile to investi- gate the compounds incorporating both 1,3,4-thiadia- zole nucleus and aroyl urea group. In the previous paper[9], a series of aroyl ureas containing 1,3,4-t…     

Crystal Structure of Phenol,2-[4（S）-4-Dihydro-4-benzyl-2-ozazolinyl]

The compound phenol,2-[4(S)-4,5-dihydro-4-phenyl-2-ozazolinyl(1,C15H13NO2) was synthesized with a simple,one step method free of water and air.It was obtained in a moderate yield from the reaction of 2-hydroxybenzonitrile with optically active amino alcohol in chloroben-zene under dry,anaerobic conditions.It belongs to the orthorhombic system,space group P212121 with a = 5.786(5),b = 10.730(5),c = 19.722(5),C15H13NO2,Mr = 239.26,V = 1224.4(12)3,Z = 4 and Dc = 1.298 mg/m3.The final R = 0.0324 for 1627 observed reflections with Ⅰ 2σ(Ⅰ) and Rw = 0.0826 for all data.The structure of compound 1 was determined by X-ray diffraction,NMR and HRMS.     

Synthesis and Structure of 5-Amino-6-(4-fluorophenylamino)-3-methylthio-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one

The title compound (C18H15FN6OS) has been synthesized and its crystal structure was determined by X-ray analysis. The crystal belongs to monoclinic system, space group P21/n with a = 13.983(10), b = 7.337(5), c = 16.702(12) (A), α = 90, β = 98.277(12), γ = 90°, V = 1696(2)(A)3, Z = 4, Dc= 1.498 g/cm3, Mr = 382.42,μ = 0.224 mm-1, F(000) = 792, the final R = 0.0362 and wR = 0.0878 for 2579 observed reflections with I ＞ 2σ(Ⅰ). In the title compound, the atoms of C(1),C(2), C(3), C(4), C(5), N(1), N(2), N(3), N(4), N(5), N(6), O(1) and S(1) form a fully delocalized system with the average deviation of 0.0307(A). There exists a part of electron delocalization over the planes of Ⅰ (pyrazolo[3,4-d]pyrimidin-4-one moiety), Ⅱ (phenyl moiety) and Ⅲ (p-fluorophenylamine moiety). In the molecule, intermolecular hydrogen bonds between N(6)-H(6)…O(1)and C( 15)-H( 15)…O( 1 ) are observed.